OpylPod
A new podcast discussing emerging technologies being developed to improve clinical trials, particularly solutions that the Opyl team is commercializing. Hosted by Opyl CEO, Michelle Gallaher, Opyl team members are featured talking about Opyl tech as well as several external experts in the clinical trial and artificial intelligence fields. Recommended for Opyl customers and shareholders to gain a deeper dive into Opyl technologies and the use case in the global drug and devices development industry.
Listen on:
Episodes
Tuesday Feb 14, 2023
Tuesday Feb 14, 2023
Join us as we delve into the world of TrialKey, a cutting-edge technology developed by Opin, with its CEO Michelle Gallaher and Head of Technology Damon Rasheed. Discover how this solution is predicting the success of clinical trials with machine learning and advanced AI, and the impact it is having on the drug development industry. Tune in to learn how you can stay ahead of the curve.
Clinical trials ready for digital disruption
Each year about 35,000 clinical trials to test and evaluate new medicines, devices, and diagnostics are launched, costing billions of dollars, yet over 90% of trials fail for a number of reasons. Two key points of failure are poor design and poor patient participation.
Artificial intelligence can significantly improve the return on investment in clinical trials and studies by designing smarter trials more likely to succeed.
Opyl's goal is to apply AI to achieve this outcome, saving medical researchers and investors precious time and money but most importantly, ensuring more new therapies reach patients who are waiting, and particularly those who have no treatment options left or simply can't wait any longer.
Check out www.opin.ai Opyl's first global clinical trial efficiency platform, helping patients to connect and participate in trials and studies anywhere in the world.